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Abstract
Background: Human papillomavirus (HPV) oncogenes E6, E7, and shorter
isoforms of E6 (E6*) are known carcinogenic factors in head and neck squa-
mous cell carcinoma (HNSCC). Little is known regarding E6* functions.
Methods: We analyzed RNA-seq data from 68 HNSCC HPV type 16-positive
tumors to determine host genes and pathways associated with E6+E7 expres-
sion (E6E7) or the percent of full-length E6 (E6%FL). Influence scores of E6E7
and E6%FL were used to test for associations with clinical variables.
Results: For E6E7, we recapitulated all major known affected pathways and
revealed additional pathways. E6%FL was found to affect mitochondrial pro-
cesses, and E6%FL influence score was significantly associated with overall
survival and tumor size.
Conclusions: HPV E6E7 and E6* result in extensive, dose-dependent compen-
satory effects and dysregulation of key cancer pathways. The switch from E6 to
E6* promotes oxidative phosphorylation, larger tumor size, and worse progno-
sis, potentially serving as a prognostic factor for HPV-positive HNSCC.
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Infection with oncogenic human papillomavirus (HPV) is
well established as a causative factor for an increasing sub-
set of head and neck squamous cell carcinoma (HNSCC),
especially in the oropharynx where HPV may now account
for up to 70% of tumors.1 The HPV “early” proteins E6 and
E7 are the main oncogenic proteins leading to HPV-related
cancers, repressing immune response and altering the cell
cycle program in the host that together allow replication
after squamous differentiation and survival despite abnor-
mal mitoses.2 HPV E6 and E7 play multiple roles, some of
them synergistic, in the tumorigenesis of cancer. E7 is well
known to bind to the retinoblastoma tumor suppressor
(pRB) and mark it for degradation,3 which results in E2F-
dependent gene transcription and further cell cycle
(S phase) activation and proliferation.4 The loss of pRB
activity could lead to p53-dependent apoptosis; however,
this is avoided by E6, which induces p53 degradation. E6
recruits the unbiquitin ligase, E6AP, which poly-
unbiquitinates the p53 tumor suppressor protein for
proteosome-mediated degradation, leading to the inhibition
of p53-dependent apoptosis and enhanced cell cycle activa-
tion.5 Besides the p53-dependent apoptosis pathway, E6
and E7 also inhibit alternative apoptosis pathways, includ-
ing anoikis and the cytokine-activated extrinsic apoptotic
pathway.6
E6 and E7 are involved in several pathways in addition
to apoptosis and the cell cycle. They cooperate to inhibit
the host immune response.7 It was shown that high-risk
HPV E6 interacts with interferon-regulatory factor 3 (IRF-
3) and inhibits its activation of downstream factors.8 Simi-
larly, E7 binds with IRF-1 and blocks its function.9 Recent
studies showed that E6 and E7 could interact withWnt sig-
naling components and regulate their signaling transduc-
tion through the canonical Wnt/β-catenin pathway.10
Independent of their cooperative functions, E6 and E7 play
roles in epigenetic modulation, telomerase activation,
DNA damage response, angiogenesis, cell immortaliza-
tion, and differentiation.11-14
E6 has multiple common transcripts, including the
longer, full-length transcript, and multiple spliced E6*
variants, the most common being a 183 bp exclusion
from positions 226 to 409 bp that was only discovered in
high-risk HPV subtypes,15,16 suggesting its role in carci-
nogenesis. Although the long E6 isoform is more com-
monly observed to be transcribed from episomal HPV,
the shorter E6* variants are more common in tumors
with HPV integrated into the host genome, which are the
majority of HNSCC cases.17 E6 splicing is induced by epi-
dermal growth factor depletion, and has been observed to
correlate with an increase in TP53 and E7 protein levels
and a decrease in pRb.15,18 Much less is known regarding
the function of E6* compared with E6 protein. Evidence
suggests that E6* in HPV18 might counteract full-length
E6 function, as it could elevate p53 levels in vivo.19
Recently, E6* was shown to increase reactive oxygen spe-
cies (ROS) and oxidative stress, which may lead to
increased DNA damage.20 In the same study, E6* was
observed to decrease superoxide dismutase isoform
2 (SOD2) and glutathione peroxidase (GPX) expression,
suggesting a cause for the oxidative stress.
Research on the oncogenic mechanisms of HPV has
been performed on amix of origin cell types (mainly cervical
but some oral), HPV types, and stages of HPV infection, and
much of it was performed in vitro, sometimes with E6 or E7
transfected in isolation. The extent to which these cumula-
tive findings remain true in oral primary carcinomas
infected with HPV16 is not fully known. Although many of
the same HPV behaviors and tumor characteristics have
been observed in cervical and oropharyngeal HPV-
associated cancers,21,22 it remains unknown whether the
findings based on cervical cells can be fully extended to the
oropharynx, which has a different tumor microenviron-
ment. Most notably, as opposed to cervical carcinomas, oro-
pharynx tumors arise within or in close proximity to a
lymph node and lymphoid follicles. Furthermore, although
many direct targets of E6 and E7 are known, the extent that
these direct effects extend to downstream pathway events or
cause compensatory effects is not known. It is also unclear
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whether most effects of E6 and E7 are dose-dependent or act
as on-off switches, although it has been shown that E6
degrades procaspase 8 in a dose-dependentmanner.23
Here, we present a genome-wide study of the relation-
ship between combined E6 and E7 mRNA levels, the per-
cent of E6 mRNA that is full-length vs E6*, and host gene
expression levels in primary HPV(+) HNSCC cancers.
This has allowed us to observe the extensive, downstream
effects of the oncogenic HPV proteins on multiple
cancer-related pathways. From the set of 18 HPV(+)
HNSCC samples collected at the University of Michigan
(UM), and 66 HPV(+) HNSCC samples from The Cancer
Genome Atlas (TCGA), we selected the total of 68 HPV16
(+) for this study (14 UM and 54 TCGA). Through this
analysis, we recaptured all of the main pathways known
to be affected by E6 and E7, whether originally described
in cervical or oropharynx cells, and identified some novel
pathways that are potentially related to the disease patho-
genesis. In addition, we propose an influence score to
assess the overall impact of E6+E7 (E6E7) and the per-
cent of E6 that is full-length (E6%FL) levels on the host
transcriptome, and identified that the E6%FL influence
score was inversely significantly associated with tumor
mutational burden (TMB) and tumor size, and associated
with better overall survival (OS). These associations rep-
resent both the direct and indirect effects of E6*, which
may involve changes in E7 translation.
2 | MATERIALS AND METHODS
2.1 | Tumor tissue acquisition
and sample preparation
HNSCC patients at UMHospital with untreated oropharynx
or oral cavity tumors between 2011 and 2013 were screened
for eligibility; those eligible were asked if willing to provide
informed consent for collection of tumor tissue and then col-
lected as described previously.17,24 Tumor tissue and blood
were collected into a cryogenic storage tube and flash frozen
in liquid nitrogen by surgical staff until storage at −80C.
The flash frozen tissues were embedded in OCT media in
vinyl cryomolds on dry ice and stored in −80C until pre-
pared for histology. H&E slides were sectioned from each
frozen tumor specimen on a cryostat and assessed by a
board-certified pathologist at the UM for degrees of cellular-
ity and necrosis. Criteria used for inclusion in the study were
a minimum of 70% cellularity and less than 10% necrosis; all
others were omitted from further study. The first 36 tumors
meeting these criteria were selected for RNA sequencing.
mRNA library preparation and RNA sequencing were per-
formed as described for these samples in Zhang et al.17
Briefly, sequencing with an Illumina HiSeq 2000 using
100 nt paired-end reads was performed by the UM DNA
Sequencing Core Facility resulting in an average of 47 mil-
lion reads per sample.
2.2 | UM RNA-seq preprocessing
RNA-seq preprocessingwas performed as described in Zhang
et al17 with an exception in the step of differential gene analy-
sis. The raw sequences were aligned to hg19 using Tophat2
v2.0.1125 using default alignment parameters. Quality control
was performed using FastQC26 and RSeQC27 before and
after alignment. Gene expression levels were quantified
using HTSeq v0.6.1p1 with the “intersection-strict” option.28
Normalization and calculation of logCPM values (log counts
per million reads mapped) were performed using the limma
Bioconductor package29 as described below.
The libraries were also aligned to HPV genomes (down-
loaded from NCBI) using spliced transcripts alignment to a
reference (STAR)30 to allow gapped alignment over splicing
junctions. STAR first-pass alignment detected the most
abundant splice junctions which were then used in the
second-pass alignment. All the quantification and analysis
below were based on the second-pass alignment. Samples
were classified as HPV(+) if they had more than 500 read
pairs aligned to any HPV genome, and HPV subtype was
determined as the subtype with the most aligned reads. We
identified 14 HPV type 16 tumors, 1 type 18, 1 type 33, and
2 type 35. Only the 14 HPV type 16 samples were used in
this study. HPV is a small genome with short oncogenes;
therefore, in order to optimize the comparability between
UM and TCGA data in terms of HPV gene expression and
splicing, all UM libraries were trimmed to the first 48 base
pairs, which was the read length of all TCGA HNSC RNA-
seq data. UM RNA-seq data are available at Gene Expres-
sion Omnibus #GSE74956.
2.3 | TCGA RNA-seq data reprocessing
RNA-seq fastq files for the 66 TCGA HPV(+) tumor sam-
ples were downloaded from CGHub. The data were
realigned and analyzed in the same way as UM RNA-seq
data described above. The samples contained 55 HPV type
16, 8 HPV type 33, and 3 HPV type 35. One TCGA sample
(TCGA-CN-A6V1, Oropharynx, HPV 16 type) was an out-
lier with extremely low E6 and E7 expression (1.64 CPM),
whereas the average expression of E6 and E7 in all other
samples was 112.5 CPM. This sample was excluded from
downstream analysis due to its outlier expression and to
avoid this sample from having a disproportionately high
effect on the results. Only the 54 HPV type16 sequencing
data were used in this study.
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2.4 | Calculating E6E7 expression
and E6%FL
The CPM (count per million) values for HPV oncogenes E6
and E7 (heretofore denoted as E6E7 expression) and the per-
cent of full-length E6 (E6%FL) were calculated as previously
described.17 The CPM values were calculated as the number
of read pairs aligned to the relevant HPV genome that inter-
sected E6 or E7, divided by the number of million reads in
the total library size. E6 alternative splicing results in multi-
ple forms of spliced E6 (referred as E6*). However, the first
intron in all forms is missing. To calculate E6%FL, we com-
puted the ratio of average coverage level in the first intron of
E6 (approximate full-length level) divided by the average
coverage level in the first exon (estimated all E6 mRNA
level), referred to as E6%FL. We identified the major donor-
acceptor sites of HPV 16 at 227 and 408 bp (for HPV16) by
STAR first-pass alignment.
2.5 | Association analysis for E6E7
expression and E6%FL vs host gene
expression
The limma R Bioconductor package was utilized to exam-
ine the association between the host gene expression and
E6E7 expression or E6%FL, respectively. Read counts of
UM and TCGA mRNA-seq data extracted by HTSeq were
transformed to logCPM values by the limma function
voom and analyzed together. Linear regression was
applied to calculate the slope and intercept of E6E7 or
E6%FL to each host gene expression using the formula:
log CPMg = α+ β0 × log CPMHPV16 +
Xn
i=1
βi × covariateið Þ
log CPMHPV16 = log CPME6E7,or, log CPME6%FL
where g = 1,…,G is a host gene, i = 1,…,n is the covariate,
α is the intercept, and β is the slope. P values of the slopes
were reported from the limma function lmfit and false
discovery rate (FDR) was calculated using the Benjamini-
Hochberg method. Genes with FDR < 0.05 were called
significant.
2.6 | Backward selection of clinical
variables
To identify the optimal set of covariates, we implemented
backward selection for high-throughput data.31 A total of
nine categorical and continuous variables were analyzed:
age, smoking status, clinical T classification (the size and
extent of the main tumor, American Joint Committee on
Cancer, seventh edition), tumor stage (based on the TNM
combination), nodal status, tumor site, sex, HPV integration,
and cohort. We grouped certain values of variables that had
an insufficient number of tumors. For example, for clinical
T classification, we grouped samples as T1 and T2 vs T3 and
T4. We analyzed samples located in oropharynx (52 tumors)
vs other sites (16 tumors, consisting of 13 oral cavity sam-
ples, 1 from larynx, and 2 from hypopharynx). Analysis by
tumor stage was performed for groups: stage IV (49 samples)
vs other stages (19 samples, consisting of stage I—1 tumor,
stage II—10 tumors, and stage III—8 tumors). Nodal status
was defined as: N0 and N1 (23 tumors: N0 = 16 and N1 = 6)
vs N2 and N3 (45 tumors: N2 = 42 and N3 = 3). The back-
ward selection procedure starts with fitting the weighted lin-
ear model of voom-transformed read counts using the lmFit
function with the empirical Bayes smoothing implemented
by the eBayes function for each of the host genes and
includes the effects of primary interest (E6E7 or E6%FL), as
well as all nine covariates. For E6%FL, the initial statistical
model included covariates for all the same variables, except
HPV integration status (8 covariates as the start point)
because integration of HPV into the host genome is a likely
effect of higher expression of E6*.32 Indeed, we observed a
significant difference in E6%FL by viral integration status
(Wilcoxon rank-sum test P value = .007). In each iteration,
the least relevant covariate was dropped if the number of its
significantly associated genes (FDR < 0.05) less than or
equal to 0.1%, or if multiple covariates had zero significant
genes, they were dropped in the following order: age,
smoking status, T classification, tumor stage, nodal status,
site, sex, HPV integration, and cohort; and the resulting
reduced model was fit again for all genes. This process was
repeated until the least relevant covariate resulted in <0.1%
associated genes. We also analyzed the correlation of log
transformed E6E7 or E6%FLwith clinical variables.
2.7 | Gene set enrichment (GSE) testing
To identify biological pathways and cellular processes
affected by E6E7 or E6 %FL levels, GSE testing was per-
formed using RNA-Enrich.33 Gene sets were Gene Ontol-
ogy (GO; Biological Process, Cellular Component, and
Molecular Function) and KEGG Pathways. To filter out
the closely related GO terms for reporting purposes, we
used the R package GO.db34 to determine relationships
among significant terms. A GO term was filtered if one or
more of its parents, children, or siblings had a higher
rank in the list. An R/Bioconductor package Pathview35
was utilized to visualize the list of driving genes in the
KEGG pathway (FDR < 0.05) as reported by the associa-
tion analysis described above.
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2.8 | Influence score calculation and
association tests between influence score
and tumor features
In order to estimate the overall influence of E6E7 or of
E6%FL on the affected host genes, we selected the genes
that were significantly correlated with E6E7 or E6%FL,
respectively, from the association analysis (FDR < 0.05).
For positively associated genes, we ranked the samples by
each of those genes' voom-transformed expression values.
For the negatively associated genes, we ranked the sam-
ples in descending order. To calculate the sample-wise
E6E7 or E6%FL influence, we summed the ranks of these
genes in each sample, centered the sum by the mean, and
then scaled it by its SD across samples. We defined the
resulting values as the influence scores. Influence scores
were used in place of mRNA levels for testing associations
with E6E7 or E6%FL for two reasons: (a) protein levels
often have poor correlation with their mRNA levels, and
we previously observed that HPV oncogene predicted
activity scores correlate better than their mRNA levels
with known HPV oncoprotein effects17 and (b) this is con-
sistent with previous reports showing transcription factor
activity scores based on their target genes provide better
estimates of the protein's activity level than the mRNA
level of the protein.36
We evaluated the association of E6E7 or E6%FL
influence scores with tumor features and demographic
variables by linear regression. Variables used in this
analysis included clinical T classification as continuous
(1-3, 4a,b), smoking (never vs smoker), HPV integra-
tion (negative vs positive), N classification (N0 or N1 vs
N2 or N3), stage (stages I-III vs stage IV), anatomical
site (oropharynx vs other), sex, age, and cohort (TCGA
vs UM). The associations between influence score
and tumor/demographic features were analyzed by
analysis of variance, and P values from the F-test were
reported.
2.9 | Calculation of TMB and survival
analysis
To evaluate the relationship between E6E7 or E6%FL expres-
sion levels or influence scores with cancer biology and clini-
cal features, we focused on the TCGA cohort due to the
availability of the mutational and survival data. The somatic
mutation data (MAF file) and clinical data of the TCGA
HNSC cohort were downloaded from the Genomic Data
Commons data portal, and the 54 HPV16(+) patients were
extracted.We calculated TMB as the total number of somatic
mutations in each patient divided by the total number of
megabases that the whole exome sequencing covered (mut
count/Mb). The correlation between TMB and E6E7, E6%FL
levels or their influence scores were assessed by the Pearson
correlation test. OS of those patients was analyzed for two
groups: the high or low levels of E6E7 or E6%FL expression
or influence scores using the R packages: survival37 and sur-
vminer.38 The median score or the optimal score cutoff
(searched by the surv_cutpoint function in survminer) was
used to define the two groups. Kaplan-Meier estimates of sur-
vival were determined, and a P value was calculated using a
univariate log-rank test. Cox proportional hazards regression
models were used for adjustment of clinical covariate vari-
ables (sex, age, clinical stage, tumor site, and smoking
status).
3 | RESULTS
3.1 | Overview of cohort and data
We used previously published mRNA sequencing results
from 18 HPV(+) tumor samples collected at UM and
66 HPV(+) samples from TCGA.39 Among these 84 sam-
ples, 69 were infected with HPV16 while the other
15 samples contained HPV33 (9), HPV35 (5) and HPV18
(1) (Table 1). The two patient populations showed no dif-
ferences by age, sex, stage, or smoking status; however,
the TCGA population did have a slightly lower propor-
tion of oropharynx tumors (P = .06; Table 1). The E6 and
E7 proteins of different HPV strains have different behav-
iors and propensity toward carcinogenesis; consistent
with these reports, we found that the expression of E6
and E7 were significantly different among HPV strains in
the 83 samples (one TCGA outlier was excluded, see the
Methods section; Figure 1A), whereas they were not sig-
nificantly different between the two cohorts (Figure 1B).
In line with the above observations, the percent of E6
transcripts that were of full-length (E6%FL) were also sig-
nificantly different by HPV strains (Figure 1C), but not
different by the two cohorts. (Figure 1D). Therefore, to
avoid confounding by HPV type, we restricted our analy-
sis to the HPV16 samples, resulting in a total of 68 com-
bined UM and TCGA samples.
Before studying the association of E6* with host
genes, we first studied associations of E6 and E7 with
host genes and pathways, many of which are previously
known. To identify host genes with E6 and E7 dose-
dependent expression levels, we calculated the overall
E6E7 log normalized read counts and performed multiple
linear regression analysis of these E6E7 expression levels
with the mRNA-seq results of the 68 samples. E6 and E7
expression levels were combined, due to their extremely
high correlation (r = .977 for HPV16 UM and r = .970 for
HPV16 TCGA).
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3.2 | E6 and E7 expression correlates
with extensive cell cycle, DNA replication
and other cancer pathway gene expression
in HNSCC
To test for association between host genes and E6E7
expression, we first investigated known clinical and
phenotypic variables that may explain additional hetero-
geneity in the data. The initial regression model included
covariates for patient age, smoking status, clinical T clas-
sification, tumor stage, nodal status, sex, anatomical site,
HPV integration status, and cohort, and the optimal
model with three covariates (cohort, HPV integration,
and sex) was selected by a backward selection approach
TABLE 1 Demographic and clinicopathologic characteristics of human papillomavirus (HPV)-positive patients from both University of















18 66 84 14 55 69
Age at diagnosis
Median (SD) 58.5 (7.3) 57 (9.2) 58 (7.7) 57 (9.7) .29
Sex
Male 17 60 77 13 49 62 1.00
Female 1 6 7 1 6 7
HPV type
HPV16 14 55 69 14 55 69 .73
HPV18 1 0 1
HPV33 1 8 9
HPV35 2 3 5
Anatomical site
Oropharynx 17 47 64 13 40 53 .06
Oral cavity 1 16 17 1 12 13
Larynx 0 1 1 0 1 1
Hypopharynx 0 2 2 0 2 2
Tumor stage
I 0 2 2 0 1 1 .75
II 1 10 11 1 9 10
III 2 7 9 2 6 8
IV 15 47 62 11 39 50
T stage
T1 1 8 1 5 6 .73
T2 7 31 6 28 34
T3 3 10 13 2 9 11
T4 7 16 23 5 12 17
N stage
N0 1 18 19 1 15 16 .16
N1 2 6 8 2 4 6
N2 11 39 50 10 33 43
N3 4 2 6 1 2 3
Smoking status
Current 3 13 16 3 10 13
Former 11 30 41 7 26 33 .64
Never 4 22 26 4 19 23
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(Supplementary Table S1).31 A total of 261 host genes
(228 upregulated and 33 downregulated) were signifi-
cantly associated with E6E7 expression (Supplementary
Table S2; FDR < 0.05). Among the 228 positively associ-
ated genes, 40 were involved in DNA replication; 21 genes
were involved in cell cycle checkpoint, whose activation
are essential for cell cycle progression; and 42 were
involved with DNA repair. The top six positively associ-
ated genes by P value were: NGFI-A binding protein
1 (NAB1), cell proliferation regulating inhibitor of protein
phosphatase 2A (CIP2A), DNA topoisomerase II alpha
(TOP2A), timeless circadian regulator (TIMELESS), DLG
associated protein 5 (DLGAP5), and cell division cycle
6 (CDC6). These results suggest that higher E6E7
FIGURE 1 A, Box plot showing the normalized RNA-seq expression level of human papillomavirus (HPV) E6+E7, denoted as log2CPM
(E6E7), in different HPV subtypes across the combined University of Michigan (UM) and The Cancer Genome Atlas (TCGA) 84 HPV-positive
head and neck squamous cell carcinoma (HNSCC) samples. B, Box plot showing the expression level of HPV E6E7 in each data cohort (UM and
TCGA) (P= .45). C, Box plot showing the normalized RNA-seq expression level of proportion of HPV E6 that is expressed in full-length
(E6%FL), in different HPV subtypes across the combined UM and TCGA 84 HPV-positive HNSCC samples. D, Box plot showing the expression
level of E6%FL in each data cohort (UM and TCGA) (P= .23) [Color figure can be viewed at wileyonlinelibrary.com]
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expression in tumors correlates with enhanced DNA rep-
lication and repair, and cell cycle progression, indicating
an extensive “dose response” to E6E7 by the host cells.
We identified 94 GO terms and 9 KEGG pathways sig-
nificantly positively associated, and 83 GO terms and
9 KEGG pathways negatively associated with E6E7
expression (FDR < 0.05; Figure 2A,B; Supplementary
Table S3). Consistent with our individual gene results, cell
cycle and DNA replication pathways were found to be
enriched with positively regulated genes by E6E7 expres-
sion (Figure 2B), and cell cycle was the most significant
KEGG pathway (odds ratio = 2.33, FDR = 1.04 × 10−21)
FIGURE 2 Bubble plot of Gene Ontology (GO) terms and KEGG pathways enriched in the genes associated with human
papillomavirus (HPV) expression of E6E7 or E6%FL, respectively. A, Ten of the most enriched GOBP (Gene Ontology in biological process
domain) terms enriched in host genes positively or negatively associated with E6E7 (or E6%FL) expression. B, Ten of the most enriched
KEGG pathways in host genes positively or negatively associated with E6E7 (or E6%FL) expression. The color of the dots denotes the
significant levels (reddish: higher significance; bluish: lower significance), and the size denotes the gene set size
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with 21 out of 88 genes positively correlated at the
FDR < 0.05 level (Supplementary Figure S1; Table S3).
Pathways known to be involved in the carcinogenic
mechanisms of E6E7 such as regulation of immune
response, cell cycle, response to cytokine, Wnt-receptor
activity, mismatch repair, nucleotide excision repair, heli-
case activity, histone binding, and histone kinase activity
(Supplementary Table S3) were also found. In addition,
novel pathways and GO terms including oxidative phos-
phorylation (OXPHOS), ribosome, mitochondrial inner
membrane, and cardiac muscle contraction were identi-
fied as negatively associated with E6E7 expression
(Figure 2; Supplementary Table S3). These results con-
firm the previously reported mechanisms of E6 and
E7-related tumorigenesis,40 and identify novel pathways
that may also contribute to E6- and E7-mediated
carcinogenesis.
3.3 | Percent of E6 that is full-length
as opposed to E6* (E6%FL) is negatively
associated with mitochondrial/oxidative
processes, ATP metabolic process,
keratinization, and inflammation
In high-risk HPV-related carcinogenesis, E6 mRNA is
most often spliced to shorter E6 spliced isoforms (E6*),
creating truncated proteins whose functions remain elu-
sive. Previous studies suggest E6* can bind to the full-
length E6 and inhibit its function in degrading TP53.41
However, it is known that an increasing percentage of
E6* predicts a more severe phenotype in cervical can-
cer.42,43 Thus, we hypothesized that E6* has an alterna-
tive carcinogenic mechanism that outweighs any tumor
suppressive function it may have, such as allowing higher
TP53 activity. In order to investigate a possible relation-
ship between E6 splicing and HNSCC carcinogenesis, we
determined the percent of E6 expression that was in the
form of the full-length isoform for each sample, which is
the reverse of percent of E6* (see the Methods section for
details). We then performed the same linear regression
analysis as above, except using E6%FL instead of E6E7.
Similar to the E6E7 analysis, we first investigated known
clinical and phenotypic variables that may explain addi-
tional heterogeneity in E6%FL (see the Methods section).
Using the backward selection process, we identified the
optimal model with the covariates of cohort and sex
(Supplementary Table S2). A total of 169 differentially
expressed genes (156 upregulated and 13 downregulated)
were significantly associated with E6%FL from this
model (Supplementary Table S4; FDR < 0.05).
GSE analysis revealed 123 GO terms and 20 KEGG
pathways negatively associated and 132 GO terms and
20 KEGG pathways (FDR < 0.05) positively associated with
E6%FL (Supplementary Table S5). As shown in Figure 2,
mitochondrial inner membrane (FDR = 1.2 × 10−43) and
oxidative phosphorylation (FDR = 1.86 × 10−26) were the
top negative terms, with other oxidoreductase-related terms
filling the other top negative terms (Supplementary
Table S5). These results suggest that mitochondrial/oxido-
reductase activity is more activated with a higher rate of
spliced E6*, which may lead to heightened oxidative stress
andDNA damage. Themost highly associated genes related
to OXPHOS were NADH:ubiquinone oxidoreductase sub-
unit AB1 (NDUFAB1). However, we did not observe a sig-
nificant association with either SOD2 or GPX, as was
previously observed. Top enriched pathways positively cor-
related with the E6%FL were chromatin and sequence-
specific DNA binding, nuclear division, and microtubule
cytoskeleton organization. Also included was stem cell pop-
ulation maintenance, which includes such genes as
NOTCH1, SMAD2& 4, SOX2, STAT3, and FOXO3.
3.4 | Percentage of E6* is positively
associated with tumor size and worse
survival
Next, we sought to investigate whether the activity level of
E6E7 or E6* has any relationship with tumor features or
survival. As E6E7 or E6* mRNA expression in each patient
may not accurately reflect the protein activity levels,
respectively,17 we calculated an influence score for each
tumor sample, defined by the level of influence E6E7 or
E6%FL has on the expression of responsive genes. Genes
significantly associated with E6E7 expression or E6%FL
(FDR < 0.05) were selected to estimate the influence scores
(see the Methods section for details). As expected, we
observed highly significant correlation between the E6E7
influence score and E6E7 mRNA expression (Figure 3A,
left: Pearson's r= 0.68, P= 2.85 × 10−10), as well as between
E6%FL influence score and E6%FL expression (Figure 3A,
right: Spearman's r = 0.58, P = 1.68 × 10−7). We examined
the relationship between E6E7 or E6* and TMB. We
hypothesized that as E6* was observed to increase oxidative
stress and DNA damage in cells, the percent of E6* would
be positively associated with TMB (E6%FL would be nega-
tively associated). We also hypothesized that E6E7 may be
negatively associated with TMB, as patients with strong E6
and E7 activity may not require as many mutations for car-
cinogenesis. To test these hypotheses, we calculated the
TMB among the 54 TCGA patients (see the Methods sec-
tion), and found that TMB had significant negative associa-
tions with both influence scores (Figure 3B: E6%FL
influence score vs TMB: Pearson's r=−0.36, P= .009; E6E7
influence score vs TMB: Pearson's r = −0.30, P = .03). As
QIN ET AL. 2383
evidence that the influence scores are more relevant to can-
cer biology than the mRNA levels, no significant associa-
tion was observed between TMB and either E6%FL or E6E7
expression levels (Figure 3C).
We then carried out multivariable linear regression
analysis to model the association of influence score with
different tumor variables, specifically with tumor site
(oropharynx [n = 52] vs other [n = 16]); tumor T
FIGURE 3 A, The correlation between human papillomavirus (HPV) oncogene expression and their corresponding influence scores
(left: E6E7 expression level vs E6E7 influence score; right: E6%FL expression level vs E6%FL influence score). The color of dots denotes the
cohort (red circle is The Cancer Genome Atlas [TCGA] and blue triangle is University of Michigan [UM] cohort). B, The correlation between
the E6E7 or E6%FL influence score and tumor mutational burden (TMB) among the TCGA cohort (left: E6%FL influence score vs TMB;
right: E6E7 influence score vs TMB. C, The correlation between E6E7 or E6%FL mRNA expression and TMB among the TCGA cohort (left:
E6%FL vs TMB; and right: E6E7 vs TMB) [Color figure can be viewed at wileyonlinelibrary.com]
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classification (stage I = 6 samples, stage II = 33 samples,
stage III = 11 samples, and stage IV = 17 samples; one
sample had undefined T classification); HPV integration
status; smoking status; sex; tumor N classification; cohort
and age. The E6%FL influence scores demonstrated a sig-
nificantly negative association with tumor clinical T clas-
sification (Figure 4A; Supplementary Table S6; P = .004),
meaning that larger tumors were associated with a higher
FIGURE 4 The association between E6%FL influence score and tumor characteristics and clinical features. A, Box plot showing the
significant difference in E6%FL influence score by clinical T classification (P = .004), tumor anatomical site (P = .003), human
papillomavirus (HPV) integration status (P = .005), and smoking status (P = .02). B, The Kaplan-Meier curves showing the significant
segregation of overall survival among TCGA patients with HPV16-positive HNSC by E6%FL influence score. Both optimal (left, N = 44 in
lower-risk group and N = 10 in higher-risk group at day 0) and median score (right, N = 27 in each subgroup at day 0) cutoffs showed that
patients with higher E6%FL influence scores had significantly better survival (Cox proportional hazards: P = .0003 and .02, respectively)
[Color figure can be viewed at wileyonlinelibrary.com]
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percent of E6*. Associations resulting in significant
unadjusted P values, but which were not significant after
multiple-testing adjustment (Figure 4A), included tumor
site (P = .004), HPV integration (P = .02) and smoking
status (P = .01). On the other hand, the E6E7 influence
score had no significant associations after multiple-
testing adjustment, and only demonstrated a borderline
significant trend with smoking status (P = .04) and tumor
site (P = .05).
The significant association between E6%FL influence
score and tumor features, especially the negative associa-
tion with tumor size, triggered us to further assess its
clinical relevance. We investigated the OS of the 54 TCGA
patients stratified by optimal or median cutoff of E6%FL
influence scores (Figure 4B). OS was significantly segre-
gated by both cutoffs (optimal cutoff: log-rank test,
P = 1.00 × 10−5; median cutoff: log-rank test, P = .02),
and patients with higher E6%FL influence scores, (lower
%E6* influence scores), had better survival. In contrast,
the mRNA level of E6%FL did not show any association
with the patients' survival (Supplementary Figure S2),
again suggesting that the E6%FL influence score rather
than the E6%FL level itself is more relative to the clinical
characteristics. After control for the clinical variables sex,
age, tumor stage, tumor site, and smoking status, the sig-
nificance remained (Cox hazard regression, P = .02 and
interquartile range HR = 0.13). In line with the fact that
E6* is associated with high-risk HPV(+) cervical cancer,
this finding suggests that the E6%FL influence score may
also serve as a clinically actionable metric in HNSCC to
distinguish patient subtypes, and help guide precision
medicine.
4 | DISCUSSION
In this study, we investigated the relationship betweenHPV
oncogene expression and hostmRNA expression inHNSCC
samples from two cohorts, and used the resulting host gene
responses to develop an influence score. This facilitated the
identification of the relationship between E6 splicing and
tumor size, TMB, and OS. We also confirmed genes and
pathways previously identified to be affected by HPV16 E6
and E7, including genes involved in DNA replication, DNA
repair and cell cycle, such as CDK2 and CLSPN (claspin),
showing that these responses to E6 and E7 expression dis-
play a correlative “dose response.” HPV16 E7 is known to
interact with two cyclin/CDK2 complexes and to inhibit the
cyclin dependent kinase inhibitors p21 and p27, leading to
the activation of CDK2 and disruption of G1/S cell cycle
checkpoint.44,45 CLSPN is essential for DNA-replication
stress response, and its degradation is associated with DNA
damage checkpoint recovery.46 Another top positively
associated gene was RBL1, which may share some func-
tional redundancy with pRB based on the high level of
sequence similarity between them, suggesting that pRB
degradation may activate a compensatory reaction. In addi-
tion to the previously known E6 and E7 transcriptional
effects, novel genes and pathways were identified, such as
mitochondrial function related biological processes. Nota-
bly, some Fanconi anemia (FA) pathway genes were found
to be significantly upregulated with the increase in E6 and
E7 expression, including FA complementation group B
(FANCB), FA complementation group C (FANCC), and FA
complementation group M (FANCM). This is consistent
with the previous finding that patients with FA have much
higher risk of HNSCC,47 and HPV(+) HNSCC patients tend
to carrymoremutations in FA genes.48
E6 mRNA splicing is a critical step in HPV-induced
tumorigenesis. However, the function and effect of trun-
cated E6 (E6*) in the disease remains unclear. Genes that
significantly correlate with E6 splicing could provide hints
of pathways that E6* affects. We did not see any evidence of
downstream effects of E6* inhibiting the degradation of
TP53, suggesting this may be a weak effect, does not occur
in HNSCCs, or does not affect the expression of down-
stream genes. The negative correlation observed with E6%
FL (ie, positive correlation with % E6*), which included
OXPHOS, ATP metabolism, mitochondrial membranes,
epithelial differentiation (keratinization), and endoplasmic
reticulum, suggests that patients with more E6* rely heavily
on OXPHOS for energy production. Interestingly, the gly-
colysis/gluconeogenesis pathwaywas also found to be nega-
tively associated with percent of E6%FL, although at a
lower significance level (FDR= 0.014). This finding appears
to contradict the Warburg effect, the tendency of tumors to
increase their use of glycolysis for energy production while
inhibiting OXPHOS in order to continue growth even in
hypoxic conditions. However, an increasing amount of evi-
dence has suggested that OXPHOS is upregulated in some
cancers,49 and one cause of the increased OXPHOS may be
the increased mtDNA content in those cancers, including
head and neck, esophageal, thyroid, ovarian, prostate, and
colorectal cancers.50 In addition, the cell differentiation pro-
cess may induce OXPHOS and mitochondrial biogenesis,
increasing ROS production,51,52 and thus inducing oxida-
tive stress and DNA damage.20 Taken together, we hypothe-
size that HPV16 E6* promotes cancer progression and
epithelial differentiation via activating the OXPHOS path-
way. The findings also suggest that OXPHOS inhibitors
may be an effective treatment for E6*-associated high-risk
HNSCC patients. Indeed, some recent studies have
highlighted mitochondrial metabolism as a target for anti-
cancer therapy.49
The higher levels of oxidative phosphorylation and
mitochondrial genes may explain the larger tumor sizes
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at diagnosis among tumors that express a higher percent
of E6*. By far, the strongest correlations of host genes
with E6* involved mitochondrial functions, including
PDK3, FH, and numerous subunits of ATP synthase,
NADH:ubiquinone oxidoreductase, and ATPase H+
transporters. We also showed that the percent of E6* is
positively correlated with TMB, suggesting higher E6*
may promote carcinogenesis and tumor growth by
increasing mutagenesis and/or allowing faster growth via
increased energy production. On the other hand, E6* is
not associated with E7 at the mRNA level, consistent
with the known report that E6* influences translation,
not RNA levels of E7.18 This could help to explain the car-
cinogenic potential of E6*.
Finally, we found that the percent of E6* is positively
associatedwithworse OS. This finding was uncovered using
the E6%FL influence scores, and survival analysis adjusting
for multiple covariates. Our findings with E6%FL influence
scores, which were not found with E6%FL mRNA expres-
sion levels, validate the clinical relevance and potential use
of our influence score as a prognostic factor. Hong et al saw
a trend in survival based on the ratio of two different shorter
isoforms of E6*, E6*I/E6*II.53 Our definition of E6*
included both of these isoforms, but with E6*I being by far
themore prominent one.
Overall, this study demonstrates the dose response
effects of E6 and E7 oncogenes on the host transcriptome.
This suggests that HPV oncogene expression levels are an
important indicator of patient prognosis in HNSCC, con-
sistent with findings in cervical cancer.54 These analyses
identified new genes and pathways affected by E6E7 or
the splicing ratio of E6, the latter of which has not been
well described. The findings based on the splicing ratio of
E6 can guide future studies of the molecular mechanisms
underlying E6*-associated carcinogenesis such as mito-
chondrial metabolism (OXPHOS). The fact that the
higher E6%FL influence score was significantly associ-
ated with a better OS in HPV16-positive patients further
supports E6* being associated with high-risk HPV(+)
tumors; we are thus optimistic to propose it as a potential
prognostic factor for HPV(+) HNSCC patients although a
larger cohort is needed for further validation. One of the
limitations of this analysis is that we cannot distinguish
between the direct influence of E6*, and the indirect
influence through increased translation of E7. Further
studies are required to investigate the correlation
between E6* and E7 at protein level and explore the
underlying oncogenic mechanisms of E6*.
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